Drug Shortage Report for CABLIVI

Last updated on 2025-01-24

Report ID 225859
Drug Identification Number 02496194
Brand name CABLIVI
Common or Proper name caplacizumab
Company Name SANOFI-AVENTIS CANADA INC
Market Status CANCELLED POST MARKET
Active Ingredient(s) CAPLACIZUMAB
Strength(s) 11MG
Dosage form(s) POWDER FOR SOLUTION KIT
Route of administration SUBCUTANEOUS INTRAVENOUS
Packaging size 1 vial/box
ATC code B01AX
ATC description
Reason for shortage Other (Please describe in comments)
Anticipated start date
Actual start date 2024-05-01
Estimated end date Unknown
Actual end date 2025-01-14
Shortage status Resolved
Updated date 2025-01-24
Company comments Business reasons
Health Canada comments
Tier 3 Status No
Company contact information email: [email protected] Telephone: 1-800-265-7927

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v5 2025-01-24 French Compare
v4 2025-01-24 English Compare
v3 2024-05-02 English Compare
v2 2024-04-22 French Compare
v1 2024-04-22 English Compare

Showing 1 to 5 of 5